The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI , an oral, once-daily ...
The Montreal-based C3i Center obtained regulatory approval from the European Medicine Agency (EMA) to produce cell therapy therapies for the European market. The company obtained a certificate of ...
MONTRÉAL, Feb. 19, 2025 (GLOBE NEWSWIRE) -- C3i Center (C3i) announces that it has obtained regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback